Skip to main content
Top
Published in: Endocrine 2/2016

01-05-2016 | Original Article

A venous thromboembolism risk assessment model for patients with Cushing’s syndrome

Authors: Marialuisa Zilio, Linda Mazzai, Maria Teresa Sartori, Mattia Barbot, Filippo Ceccato, Viviana Daidone, Alessandra Casonato, Graziella Saggiorato, Franco Noventa, Laura Trementino, Paolo Prandoni, Marco Boscaro, Giorgio Arnaldi, Carla Scaroni

Published in: Endocrine | Issue 2/2016

Login to get access

Abstract

Cushing’s syndrome (CS) is associated with an incidence of venous thromboembolism (VTE) about ten times higher than in the normal population. The aim of our study was to develop a model for identifying CS patients at higher risk of VTE. We considered clinical, hormonal, and coagulation data from 176 active CS patients and used a forward stepwise logistic multivariate regression analysis to select the major independent risk factors for thrombosis. The risk of VTE was calculated as a ‘CS-VTE score’ from the sum of points of present risk factors. VTE developed in 20 patients (4 pulmonary embolism). The group of CS patients with VTE were older (p < 0.001) and had more cardiovascular events (p < 0.05), infections and reduced mobility (both p < 0.001), higher midnight plasma cortisol levels (p < 0.05), and shorter APTT (p < 0.01) than those without. We identified six major independent risk factors for VTE: age ≥69 years and reduced mobility were given two points each, whereas acute severe infections, previous cardiovascular events, midnight plasma cortisol level >3.15 times the normality and shortened APTT were given one point each. A CS-VTE score <2 anticipated no risk of VTE; a CS-VTE score of two mild risk (10 %); a CS-VTE score of three moderate risk (46 %); a CS-VTE score ≥4 high risk (85 %). Considering a score ≥3 as predictive of VTE, 94 % of the patients were correctly classified. A simple score helps stratify the VTE risk in CS patients and identify those who could benefit from thromboprophylaxis.
Literature
1.
go back to reference P. Miljic, D. Miljic, J.W. Cain, M. Korbonits, V. Popovic, Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 11, 21–30 (2012)PubMed P. Miljic, D. Miljic, J.W. Cain, M. Korbonits, V. Popovic, Pathogenesis of vascular complications in Cushing’s syndrome. Hormones 11, 21–30 (2012)PubMed
2.
go back to reference T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. 61, 768–777 (2004)CrossRef T. Mancini, B. Kola, F. Mantero, M. Boscaro, G. Arnaldi, High cardiovascular risk in patients with Cushing’s syndrome according to 1999 WHO/ISH guidelines. Clin. Endocrinol. 61, 768–777 (2004)CrossRef
3.
go back to reference G. Arnaldi, T. Mancini, B. Polenta, M. Boscaro, Cardiovascular risk in Cushing’s syndrome. Pituitary 7, 253–256 (2004)CrossRefPubMed G. Arnaldi, T. Mancini, B. Polenta, M. Boscaro, Cardiovascular risk in Cushing’s syndrome. Pituitary 7, 253–256 (2004)CrossRefPubMed
4.
go back to reference O.M. Dekkers, E. Horváth-Puhó, J.O. Jørgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sørensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed O.M. Dekkers, E. Horváth-Puhó, J.O. Jørgensen, S.C. Cannegieter, V. Ehrenstein, J.P. Vandenbroucke, A.M. Pereira, H.T. Sørensen, Multisystem morbidity and mortality in Cushing’s syndrome: a cohort study. J. Clin. Endocrinol. Metab. 98, 2277–2284 (2013)CrossRefPubMed
5.
go back to reference R. Van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78, 481–488 (2013)CrossRef R. Van der Pas, F.W. Leebeek, L.J. Hofland, W.W. de Herder, R.A. Feelders, Hypercoagulability in Cushing’s syndrome: prevalence, pathogenesis and treatment. Clin. Endocrinol. 78, 481–488 (2013)CrossRef
6.
go back to reference B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. Buller, D.P. Brandjes, Hypercoagulable state in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743–2750 (2009)CrossRefPubMed B. Van Zaane, E. Nur, A. Squizzato, O.M. Dekkers, M.T. Twickler, E. Fliers, V.E. Gerdes, H.R. Buller, D.P. Brandjes, Hypercoagulable state in Cushing’s syndrome: a systematic review. J. Clin. Endocrinol. Metab. 94, 2743–2750 (2009)CrossRefPubMed
7.
go back to reference S.A. Johannesdottir, E. Horváth-Puhó, O.M. Dekkers, S.C. Cannegieter, J.O. Jørgensen, V. Ehrenstein, J.P. Vandenbroucke, L. Pedersen, H.T. Sørensen, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173, 743–752 (2013)CrossRefPubMed S.A. Johannesdottir, E. Horváth-Puhó, O.M. Dekkers, S.C. Cannegieter, J.O. Jørgensen, V. Ehrenstein, J.P. Vandenbroucke, L. Pedersen, H.T. Sørensen, Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study. JAMA Intern Med 173, 743–752 (2013)CrossRefPubMed
8.
go back to reference D.J. Stuijver, B. van Zaane, R.A. Feelders, J. Debeij, S.C. Cannegieter, A.R. Hermus, G. van den Berg, A.M. Pereira, W.W. de Herder, M.A. Wagenmakers, M.N. Kerstens, P.M. Zelissen, E. Fliers, N. Schaper, M.L. Drent, O.M. Dekkers, V.E. Gerdes, Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J. Clin. Endocrinol. Metab. 96, 3525–3532 (2011)CrossRefPubMed D.J. Stuijver, B. van Zaane, R.A. Feelders, J. Debeij, S.C. Cannegieter, A.R. Hermus, G. van den Berg, A.M. Pereira, W.W. de Herder, M.A. Wagenmakers, M.N. Kerstens, P.M. Zelissen, E. Fliers, N. Schaper, M.L. Drent, O.M. Dekkers, V.E. Gerdes, Incidence of venous thromboembolism in patients with Cushing’s syndrome: a multicenter cohort study. J. Clin. Endocrinol. Metab. 96, 3525–3532 (2011)CrossRefPubMed
9.
go back to reference D.J. Brotman, J.P. Girod, A. Posch, J.T. Jani, J.V. Patel, M. Gupta, G.Y. Lip, S. Reddy, T.S. Kickler, Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb. Res. 118, 247–252 (2006)CrossRefPubMed D.J. Brotman, J.P. Girod, A. Posch, J.T. Jani, J.V. Patel, M. Gupta, G.Y. Lip, S. Reddy, T.S. Kickler, Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb. Res. 118, 247–252 (2006)CrossRefPubMed
10.
go back to reference L.M. Fatti, B. Bottasso, C. Invitti, R. Coppola, F. Cavagnini, P.M. Mannucci, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J. Endocrinol. Invest. 23, 145–150 (2000)CrossRefPubMed L.M. Fatti, B. Bottasso, C. Invitti, R. Coppola, F. Cavagnini, P.M. Mannucci, Markers of activation of coagulation and fibrinolysis in patients with Cushing’s syndrome. J. Endocrinol. Invest. 23, 145–150 (2000)CrossRefPubMed
11.
go back to reference M. Franchini, G. Lippi, F. Manzato, P.P. Vescovi, G. Targher, Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439–451 (2010)CrossRefPubMed M. Franchini, G. Lippi, F. Manzato, P.P. Vescovi, G. Targher, Hemostatic abnormalities in endocrine and metabolic disorders. Eur. J. Endocrinol. 162, 439–451 (2010)CrossRefPubMed
12.
go back to reference H.E. Sjoberg, M. Blomback, P.O. Granberg, Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Medica Scandinavica 199, 95–98 (1976)CrossRefPubMed H.E. Sjoberg, M. Blomback, P.O. Granberg, Thromboembolic complications, heparin treatment and increase in coagulation factors in Cushing’s syndrome. Acta Medica Scandinavica 199, 95–98 (1976)CrossRefPubMed
13.
go back to reference G.M. Patrassi, Z.R. Dal Bo, M. Boscaro, S. Martinelli, A. Girolami, Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb. Haemost. 54, 518–520 (1985)PubMed G.M. Patrassi, Z.R. Dal Bo, M. Boscaro, S. Martinelli, A. Girolami, Further studies on the hypercoagulable state of patients with Cushing’s syndrome. Thromb. Haemost. 54, 518–520 (1985)PubMed
14.
go back to reference Z.R. Dal Bo, L. Fornasiero, M. Boscaro, G. Cappellato, F. Fabris, A. Girolami, Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb. Haemost. 47, 116–117 (1982) Z.R. Dal Bo, L. Fornasiero, M. Boscaro, G. Cappellato, F. Fabris, A. Girolami, Increased factor VIII associated activities in Cushing’s syndrome: a probable hypercoagulable state. Thromb. Haemost. 47, 116–117 (1982)
15.
go back to reference A. Casonato, E. Pontara, M. Boscaro, N. Sonino, F. Sartorello, S. Ferasin, A. Girolami, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul. Fibrinolysis 10, 145–151 (1999)CrossRefPubMed A. Casonato, E. Pontara, M. Boscaro, N. Sonino, F. Sartorello, S. Ferasin, A. Girolami, Abnormalities of von Willebrand factor are also part of the prothrombotic state of Cushing’s syndrome. Blood Coagul. Fibrinolysis 10, 145–151 (1999)CrossRefPubMed
16.
go back to reference B. Ambrosi, A. Sartorio, A. Pizzocaro, E. Passini, B. Bottasso, A. Federici, Evaluation 307 of haemostatic and fibrinolytic markers in patients with Cushing’s syndrome and in patients with adrenal incidentaloma. Exp. Clin. Endocrinol. Diabetes 108, 294–298 (2000)CrossRefPubMed B. Ambrosi, A. Sartorio, A. Pizzocaro, E. Passini, B. Bottasso, A. Federici, Evaluation 307 of haemostatic and fibrinolytic markers in patients with Cushing’s syndrome and in patients with adrenal incidentaloma. Exp. Clin. Endocrinol. Diabetes 108, 294–298 (2000)CrossRefPubMed
17.
go back to reference G.M. Patrassi, M.T. Sartori, M.L. Viero, L. Scarano, M. Boscaro, A. Girolami, The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul. Fibrinolysis 3, 789–793 (1992)CrossRefPubMed G.M. Patrassi, M.T. Sartori, M.L. Viero, L. Scarano, M. Boscaro, A. Girolami, The fibrinolytic potential in patients with Cushing’s disease: a clue to their hypercoagulable state. Blood Coagul. Fibrinolysis 3, 789–793 (1992)CrossRefPubMed
18.
go back to reference C. Erem, I. Nuhoglu, M. Yilmaz, M. Kocak, A. Demirel, O. Ucuncu, H.O. Ersoz, Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J. Endocrinol. Invest. 32, 169–174 (2009)CrossRefPubMed C. Erem, I. Nuhoglu, M. Yilmaz, M. Kocak, A. Demirel, O. Ucuncu, H.O. Ersoz, Blood coagulation and fibrinolysis in patients with Cushing’s syndrome: increased plasminogen activator inhibitor-1, decreased tissue factor pathway inhibitor and unchanged thrombin-activatable fibrinolysis inhibitor levels. J. Endocrinol. Invest. 32, 169–174 (2009)CrossRefPubMed
19.
go back to reference D. Kastelan, T. Dusek, I. Kraljevic, O. Polasek, Z. Giljevic, M. Solak, S.Z. Salek, J. Jelcic, I. Aganovic, M. Korsic, Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36, 70–74 (2009)CrossRefPubMed D. Kastelan, T. Dusek, I. Kraljevic, O. Polasek, Z. Giljevic, M. Solak, S.Z. Salek, J. Jelcic, I. Aganovic, M. Korsic, Hypercoagulability in Cushing’s syndrome: the role of specific haemostatic and fibrinolytic markers. Endocrine 36, 70–74 (2009)CrossRefPubMed
20.
go back to reference S. Koutroumpi, L. Spiezia, N. Albiger, M. Barbot, M. Bon, S. Maggiolo, S. Gavasso, P. Simioni, A. Frigo, F. Mantero, C. Scaroni, Thrombin generation in Cushing’s syndrome: do the conventional clotting indices tell the whole truth? Pituitary 17, 68–75 (2014)CrossRefPubMed S. Koutroumpi, L. Spiezia, N. Albiger, M. Barbot, M. Bon, S. Maggiolo, S. Gavasso, P. Simioni, A. Frigo, F. Mantero, C. Scaroni, Thrombin generation in Cushing’s syndrome: do the conventional clotting indices tell the whole truth? Pituitary 17, 68–75 (2014)CrossRefPubMed
21.
go back to reference B. Van Zaane, E. Nur, A. Squizzato, V.E. Gerdes, H.R. Büller, O.M. Dekkers, D.P. Brandjes, Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J. Thromb. Haemost. 8, 2483–2493 (2010)CrossRefPubMed B. Van Zaane, E. Nur, A. Squizzato, V.E. Gerdes, H.R. Büller, O.M. Dekkers, D.P. Brandjes, Systematic review on the effect of glucocorticoid use on procoagulant, anti-coagulant and fibrinolytic factors. J. Thromb. Haemost. 8, 2483–2493 (2010)CrossRefPubMed
22.
go back to reference A.M. Isidori, M. Minnetti, E. Sbardella, C. Graziadio, A. Grossman, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur. J. Endocrinol. pii: EJE-15-0308. [Epub ahead of print] PubMed PMID: 25987566 (2015) A.M. Isidori, M. Minnetti, E. Sbardella, C. Graziadio, A. Grossman, Mechanisms in endocrinology: the spectrum of haemostatic abnormalities in glucocorticoid excess and defect. Eur. J. Endocrinol. pii: EJE-15-0308. [Epub ahead of print] PubMed PMID: 25987566 (2015)
23.
go back to reference S. Koutroumpi, V. Daidone, M.T. Sartori, M.G. Cattini, N.M. Albiger, G. Occhi, S. Ferasin, A. Frigo, F. Mantero, A. Casonato, C. Scaroni, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 16, 175–181 (2013)CrossRefPubMed S. Koutroumpi, V. Daidone, M.T. Sartori, M.G. Cattini, N.M. Albiger, G. Occhi, S. Ferasin, A. Frigo, F. Mantero, A. Casonato, C. Scaroni, Venous thromboembolism in patients with Cushing’s syndrome: need of a careful investigation of the prothrombotic risk profile. Pituitary 16, 175–181 (2013)CrossRefPubMed
24.
go back to reference M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 87, 3662–3666 (2002)PubMed M. Boscaro, N. Sonino, A. Scarda, L. Barzon, F. Fallo, M.T. Sartori, G.M. Patrassi, A. Girolami, Anticoagulant prophylaxis markedly reduces thromboembolic complications in Cushing’s syndrome. J. Clin. Endocrinol. Metab. 87, 3662–3666 (2002)PubMed
25.
go back to reference G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRefPubMed G. Arnaldi, A. Angeli, A.B. Atkinson, X. Bertagna, F. Cavagnini, G.P. Chrousos, G.A. Fava, J.W. Findling, R.C. Gaillard, A.B. Grossman, B. Kola, A. Lacroix, T. Mancini, F. Mantero, J. Newell-Price, L.K. Nieman, N. Sonino, M.L. Vance, A. Giustina, M. Boscaro, Diagnosis and complications of Cushing’s syndrome: a consensus statement. J. Clin. Endocrinol. Metab. 88, 5593–5602 (2003)CrossRefPubMed
26.
go back to reference M. Boscaro, G. Arnaldi, Approach to the patient with possible Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3121–3131 (2009)CrossRefPubMed M. Boscaro, G. Arnaldi, Approach to the patient with possible Cushing’s syndrome. J. Clin. Endocrinol. Metab. 94, 3121–3131 (2009)CrossRefPubMed
27.
go back to reference S. Barbar, F. Noventa, V. Rossetto, A. Ferrari, B. Brandolin, M. Perlati, E. De Bon, D. Tormene, A. Pagnan, P. Prandoni, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J. Thromb. Haemost. 8, 2450–2457 (2010)CrossRefPubMed S. Barbar, F. Noventa, V. Rossetto, A. Ferrari, B. Brandolin, M. Perlati, E. De Bon, D. Tormene, A. Pagnan, P. Prandoni, A risk assessment model for the identification of hospitalized medical patients at risk for venous thromboembolism: the Padua prediction score. J. Thromb. Haemost. 8, 2450–2457 (2010)CrossRefPubMed
28.
go back to reference L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRefPubMedPubMedCentral L.K. Nieman, B.M. Biller, J.W. Findling, J. Newell-Price, M.O. Savage, P.M. Stewart, V.M. Montori, The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 1526–1540 (2008)CrossRefPubMedPubMedCentral
29.
go back to reference M. Barbot, N. Albiger, F. Ceccato, M. Zilio, A.C. Frigo, L. Denaro, F. Mantero, C. Scaroni, Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17, 109–117 (2014)CrossRefPubMed M. Barbot, N. Albiger, F. Ceccato, M. Zilio, A.C. Frigo, L. Denaro, F. Mantero, C. Scaroni, Combination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole? Pituitary 17, 109–117 (2014)CrossRefPubMed
30.
go back to reference F. Ceccato, G. Antonelli, M. Barbot, M. Zilio, L. Mazzai, R. Gatti, M. Zaninotto, F. Mantero, M. Boscaro, M. Plebani, C. Scaroni, The diagnostic performance of urinary free cortisol is better than the cortisol/cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC-MS/MS method in routine clinical practice. Eur. J. Endocrinol. 171, 1–7 (2014)CrossRefPubMed F. Ceccato, G. Antonelli, M. Barbot, M. Zilio, L. Mazzai, R. Gatti, M. Zaninotto, F. Mantero, M. Boscaro, M. Plebani, C. Scaroni, The diagnostic performance of urinary free cortisol is better than the cortisol/cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC-MS/MS method in routine clinical practice. Eur. J. Endocrinol. 171, 1–7 (2014)CrossRefPubMed
31.
go back to reference F. Ceccato, M. Barbot, M. Zilio, S. Ferasin, G. Occhi, A. Daniele, S. Mazzocut, M. Iacobone, C. Betterle, F. Mantero, C. Scaroni, Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur. J. Endocrinol. 169, 31–36 (2013)CrossRefPubMed F. Ceccato, M. Barbot, M. Zilio, S. Ferasin, G. Occhi, A. Daniele, S. Mazzocut, M. Iacobone, C. Betterle, F. Mantero, C. Scaroni, Performance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiency. Eur. J. Endocrinol. 169, 31–36 (2013)CrossRefPubMed
32.
go back to reference A. Casonato, E. Pontara, F. Sartorello, M.G. Cattini, M.T. Sartori, R. Padrini, A. Girolami, Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 99, 180–184 (2002)CrossRefPubMed A. Casonato, E. Pontara, F. Sartorello, M.G. Cattini, M.T. Sartori, R. Padrini, A. Girolami, Reduced von Willebrand factor survival in type Vicenza von Willebrand disease. Blood 99, 180–184 (2002)CrossRefPubMed
33.
go back to reference M.T. Sartori, C. Danesin, G. Saggiorato, D. Tormene, P. Simioni, L. Spiezia, G.M. Patrassi, A. Girolami, The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost. 9, 299–307 (2003)CrossRefPubMed M.T. Sartori, C. Danesin, G. Saggiorato, D. Tormene, P. Simioni, L. Spiezia, G.M. Patrassi, A. Girolami, The PAI-1 gene 4G/5G polymorphism and deep vein thrombosis in patients with inherited thrombophilia. Clin. Appl. Thromb. Hemost. 9, 299–307 (2003)CrossRefPubMed
34.
go back to reference J.C. Gill, J. Endres-Brooks, P.J. Bauer, W.J. Marks Jr, R.R. Montgomery, The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691–1695 (1987)PubMed J.C. Gill, J. Endres-Brooks, P.J. Bauer, W.J. Marks Jr, R.R. Montgomery, The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood 69, 1691–1695 (1987)PubMed
35.
go back to reference A. Casonato, V. Daidone, F. Sartorello, N. Albiger, C. Romualdi, F. Mantero, A. Pagnan, C. Scaroni, Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br. J. Haematol. 140, 230–235 (2008)CrossRefPubMed A. Casonato, V. Daidone, F. Sartorello, N. Albiger, C. Romualdi, F. Mantero, A. Pagnan, C. Scaroni, Polymorphisms in von Willebrand factor gene promoter influence the glucocorticoid-induced increase in von Willebrand factor: the lesson learned from Cushing syndrome. Br. J. Haematol. 140, 230–235 (2008)CrossRefPubMed
36.
go back to reference P. Simioni, A. Scudeller, P. Radossi, S. Gavasso, B. Girolami, D. Tormene, A. Girolami, Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb. Haemost. 75, 422–426 (1996)PubMed P. Simioni, A. Scudeller, P. Radossi, S. Gavasso, B. Girolami, D. Tormene, A. Girolami, Pseudo-homozygous activated protein C resistance due to double heterozygous factor V defect (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds. Thromb. Haemost. 75, 422–426 (1996)PubMed
37.
go back to reference P. Simioni, D. Tormene, D. Manfrin, S. Gavasso, S. Luni, D. Stocco, A. Girolami, Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br. J. Haematol. 103, 1045–1450 (1998)CrossRefPubMed P. Simioni, D. Tormene, D. Manfrin, S. Gavasso, S. Luni, D. Stocco, A. Girolami, Prothrombin antigen levels in symptomatic and asymptomatic carriers of the 20210A prothrombin variant. Br. J. Haematol. 103, 1045–1450 (1998)CrossRefPubMed
38.
go back to reference J.A. Hanley, B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982)CrossRefPubMed J.A. Hanley, B.J. McNeil, The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 143, 29–36 (1982)CrossRefPubMed
39.
go back to reference S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, Pasireotide B2305 Study Group: high variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. 80, 261–269 (2014)CrossRef S. Petersenn, J. Newell-Price, J.W. Findling, F. Gu, M. Maldonado, K. Sen, L.R. Salgado, A. Colao, B.M. Biller, Pasireotide B2305 Study Group: high variability in baseline urinary free cortisol values in patients with Cushing’s disease. Clin. Endocrinol. 80, 261–269 (2014)CrossRef
40.
go back to reference L. Trementino, G. Appolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166, 35–42 (2012)CrossRefPubMed L. Trementino, G. Appolloni, C. Concettoni, M. Cardinaletti, M. Boscaro, G. Arnaldi, Association of glucocorticoid receptor polymorphism A3669G with decreased risk of developing diabetes in patients with Cushing’s syndrome. Eur. J. Endocrinol. 166, 35–42 (2012)CrossRefPubMed
41.
go back to reference H. Raff, J.L. Raff, J.W. Findling, Late-night salivary cortisol as a screening test for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 83, 2681–2686 (1998)PubMed H. Raff, J.L. Raff, J.W. Findling, Late-night salivary cortisol as a screening test for Cushing’s syndrome. J. Clin. Endocrinol. Metab. 83, 2681–2686 (1998)PubMed
42.
go back to reference P. Restituto, J.C. Galofré, M.J. Gil, C. Mugueta, S. Santos, J.I. Monreal, N. Varo, Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. Clin. Biochem. 41, 688–692 (2008)CrossRefPubMed P. Restituto, J.C. Galofré, M.J. Gil, C. Mugueta, S. Santos, J.I. Monreal, N. Varo, Advantage of salivary cortisol measurements in the diagnosis of glucocorticoid related disorders. Clin. Biochem. 41, 688–692 (2008)CrossRefPubMed
Metadata
Title
A venous thromboembolism risk assessment model for patients with Cushing’s syndrome
Authors
Marialuisa Zilio
Linda Mazzai
Maria Teresa Sartori
Mattia Barbot
Filippo Ceccato
Viviana Daidone
Alessandra Casonato
Graziella Saggiorato
Franco Noventa
Laura Trementino
Paolo Prandoni
Marco Boscaro
Giorgio Arnaldi
Carla Scaroni
Publication date
01-05-2016
Publisher
Springer US
Published in
Endocrine / Issue 2/2016
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-015-0665-z

Other articles of this Issue 2/2016

Endocrine 2/2016 Go to the issue